Arcus Biosciences, Inc. (RCUS) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $23.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality.
Arcus Biosciences is a late clinical-stage biopharmaceutical company developing differentiated oncology and inflammation molecules, with lead programs casdatifan (HIF-2α, two Phase 3 trials in ccRCC), quemliclustat (CD73, Phase 3 in pancreatic cancer), and... Read more
Sell if holding. Engine safety override at $23.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality. Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 4.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Arcus Biosciences, Inc.
Latest news
- NEWS Arcus Biosciences Enters Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb; Will Supply Casdat — benzinga Jun 3, 2026 positive
- NEWS Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35 — benzinga May 18, 2026 positive
- NEWS Morgan Stanley Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $22 — benzinga May 11, 2026 neutral
- NEWS Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34 — benzinga May 7, 2026 positive
- NEWS Arcus Biosciences Q1 EPS $(1.02) Misses $(0.93) Estimate, Sales $17.000M Miss $29.484M Estimate — benzinga May 5, 2026 negative
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyGilead10-K Item 1A: 'We expect to depend on our collaboration with Gilead for the research, development, manufacture and commercialization of certain of our investigational products. If this collaboration is not successful, our business could be adversely affected.'
- HIGHSupplierWuXi Biologics10-K Item 1: 'we agreed, as part of the WuXi PD-1 Agreement, that WuXi Biologics would be our exclusive manufacturer of zimberelimab drug substance with respect to clinical and commercial supplies until a certain number of years after marketing approval'
Material Events(8-K, last 90d)
- 2026-03-23Item 5.02MEDIUMOn March 17, 2026, Jennifer Jarrett (Chief Operating Officer) resigned effective March 30, 2026, to pursue other opportunities. She will provide advisory services through June 30, 2026. No successor named. No disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Revenue shrinking — -39.3% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -156.4%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $23.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality. Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $22.04. Score 4.1/10, moderate confidence.
Take-profit target: $31.10 (+31.2% upside). Prior stop was $22.04. Stop-loss: $22.04.
Concentration risk — Counterparty: Gilead; Concentration risk — Supplier: WuXi Biologics; Quality below floor (2.7 < 4.0).
Arcus Biosciences, Inc. trades at a P/E of N/A (forward -6.9). TrendMatrix value score: 6.1/10. Verdict: Sell.
18 analysts cover RCUS with a consensus score of 4.1/5. Average price target: $36.
What does Arcus Biosciences, Inc. do?Arcus Biosciences is a late clinical-stage biopharmaceutical company developing differentiated oncology and...
Arcus Biosciences is a late clinical-stage biopharmaceutical company developing differentiated oncology and inflammation molecules, with lead programs casdatifan (HIF-2α, two Phase 3 trials in ccRCC), quemliclustat (CD73, Phase 3 in pancreatic cancer), and domvanalimab/zimberelimab (anti-TIGIT/PD-1, Phase 3 in NSCLC). The Gilead collaboration funds a significant portion of development costs and controls ex-U.S. commercialization rights for quemliclustat, domvanalimab, and zimberelimab. The company has no approved products and generates revenue primarily from collaboration payments.